Institute of Applied Physiology, Ulm University, Ulm, Germany.
Boehringer Ingelheim Pharma GmbH & Co. KG, Div. Research Germany, Biberach an der Riss, Germany.
Transl Psychiatry. 2023 Jul 5;13(1):243. doi: 10.1038/s41398-023-02541-z.
The anterior cingulate cortex (ACC) has been implicated in attention deficit hyperactivity disorder (ADHD). More specifically, an appropriate balance of excitatory and inhibitory activity in the ACC may be critical for the control of impulsivity, hyperactivity, and sustained attention which are centrally affected in ADHD. Hence, pharmacological augmentation of parvalbumin- (PV) or somatostatin-positive (Sst) inhibitory ACC interneurons could be a potential treatment strategy. We, therefore, tested whether stimulation of G-protein-coupled receptors (GPCRs) in these interneurons could improve attention or impulsivity assessed with the 5-choice-serial reaction-time task in male mice. When challenging impulse control behaviourally or pharmacologically, activation of the chemogenetic GPCR hM3Dq in ACC PV-cells caused a selective decrease of active erroneous-i.e. incorrect and premature-responses, indicating improved attentional and impulse control. When challenging attention, in contrast, omissions were increased, albeit without extension of reward latencies or decreases of attentional accuracy. These effects largely resembled those of the ADHD medication atomoxetine. Additionally, they were mostly independent of each other within individual animals. GPCR activation in ACC PV-cells also reduced hyperactivity. In contrast, if hM3Dq was activated in Sst-interneurons, no improvement of impulse control was observed, and a reduction of incorrect responses was only induced at high agonist levels and accompanied by reduced motivational drive. These results suggest that the activation of GPCRs expressed specifically in PV-cells of the ACC may be a viable strategy to improve certain aspects of sustained attention, impulsivity and hyperactivity in ADHD.
扣带前皮质(ACC)被认为与注意缺陷多动障碍(ADHD)有关。更具体地说,ACC 中兴奋性和抑制性活动的适当平衡可能对冲动控制、多动和持续注意力的控制至关重要,而这些都是 ADHD 的核心症状。因此,药物增强 PV-(PV)或生长抑素阳性(Sst)抑制性 ACC 中间神经元可能是一种潜在的治疗策略。因此,我们测试了刺激这些中间神经元中的 G 蛋白偶联受体(GPCR)是否可以改善雄性小鼠的 5 选择连续反应时间任务评估的注意力或冲动性。当在行为或药理学上挑战冲动控制时,ACC PV 细胞中的化学遗传 GPCR hM3Dq 的激活导致活性错误反应(即不正确和过早反应)的选择性减少,表明注意力和冲动控制得到改善。相比之下,当注意力受到挑战时,虽然没有延长奖励潜伏期或降低注意力准确性,但遗漏增加了。这些影响与 ADHD 药物托莫西汀的影响非常相似。此外,它们在个体动物之间大多是相互独立的。ACC PV 细胞中的 GPCR 激活还减少了多动。相比之下,如果 hM3Dq 在 Sst 中间神经元中被激活,则观察不到冲动控制的改善,并且仅在高激动剂水平下诱导减少错误反应,并伴有动机驱动降低。这些结果表明,特异性激活 ACC 中 PV 细胞的 GPCR 可能是改善 ADHD 中持续注意力、冲动性和多动性的某些方面的可行策略。